Post by partimefriend on Feb 21, 2020 19:43:33 GMT -5
pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/2020/files/reports/jp_morgan_post_conference_article_pack.pdf
Look at page 9 to see AMG 890 comments.
38th Annual J.P. Morgan
Healthcare Conference
Review
From page 9
However, rapidly advancing a cancer drug in
a subset of patients with a specific tumor type
is different from quickly developing a drug for
a large group of patients with cardiovascular
disease. But Amgen is optimistic that it can move
forward faster in that therapeutic area, which it is
trying to do with the Phase I candidate AMG 890
– a small interfering RNA (siRNA) drug that targets
lipoprotein(a), or Lp(a).
“I think the way forward there comes back to
genetics and allied technologies,” Reese said. “In
the Lp(a) program [we’re] using genetics and other
technologies to say here are the patients we really
think are the highest risk that are going to benefit
the most, so you can design a very efficient
development program.”
While cardiovascular outcomes studies may still
be required to confirm safety in a big patient
population, he said identifying trial participants
based on genetic markers may mean that
outcomes studies do not have to be as large at the
FOURIER outcomes trial that enrolled over 27,000
patients to confirm the cardiovascular benefits of
Amgen’s PCSK9 inhibitor Repatha (evolocumab).
(Also see “Is Amgen’s FOURIER Enough For
Physicians, Payers To Expand Repatha Use?” -
Scrip, 17 Mar, 2017.)